Cipla aims to double sales of respiratory drugs by 2020
Advertisement
Advertisement
India's fourth-largest drug maker Cipla expects its respiratory drug sales to more than double by 2020.The company aims to achieve this with Seroflo, a version of GSK’s Advair inhaler.
It had launched the product in seven countries so far, and had planned to launch it first in the UK which is touted as the biggest market in the EU for asthma drugs.
Cipla CEO Subhanu Saxena said the company had not changed its sales forecast for Seroflo.
"It would have been nice to be first, obviously. But we are still pretty much in line with our own timelines," Saxena told Reuters in an interview at Cipla's headquarters.
Advertisement
Saxena said the company plans to enter Latin America and Eastern Europe next. "I don't want any market to have more than 20-30 percent exposure for Cipla," he said.
(Image credit: Indiatimes)
Advertisement
- A couple accidentally shipped their cat in an Amazon return package. It arrived safely 6 days later, hundreds of miles away.
- A centenarian who starts her day with gentle exercise and loves walks shares 5 longevity tips, including staying single
- 2 states where home prices are falling because there are too many houses and not enough buyers
- Rupee declines 5 paise to 83.43 against US dollar in early trade
- Election Commission issues notification for sixth phase of Lok Sabha polls
- 6 Coffee recipes you should try this summer
- "To sit and talk in the box...!" Kohli's message to critics as RCB wrecks GT in IPL Match 45
- 7 Nutritious and flavourful tiffin ideas to pack for school
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market